Shots:

• On Apr 02- 2020- EMA’s CHMP has recommended Gilead’s Remdesivir to be used for treating COVID-19 in compassionate use programmes in the EU
• Compassionate use programmes are intended to provide patients access to therapies that are under development and have not yet received a marketing authorization. The CHMP encourages Gilead to make remdesivir available in a transparent way to those Member States wishing to take part in international clinical studies or treat patients in compassionate use programmes
• Estonia- Greece- the Netherlands and Romania requested CHMP’s opinion on the conditions under which early access to Remdesivir via compassionate use could be offered to patients with COVID-19

Click here ­to­ read full press release/ article 

 Ref: EMA | Image: Gilead